title: Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients.
abstract: Nine patients with duodenal ulcer were on separate occasions given omeprazole, 20 mg orally, 10 mg intravenously (IV), and 40 mg IV once daily for 5 days. On day 1, the median reduction of 24-hour intragastric acidity was 42.2% for the 20-mg oral dose and 54.8% and 88.4% for the two IV doses, respectively, but the between-patient variability was considerable for all three doses. On day 5, the degree of reduction had increased for all three doses to a median value of 99.9% for the 20-mg oral dose and 95.7% and 99.9% for the two IV doses, respectively. Plasma omeprazole concentrations increased significantly from day 1 to day 5 only for the 20-mg oral and 40-mg IV doses. Thus, the increased pharmacological effect of omeprazole during repeated once daily administration can only partly be explained by increased plasma concentrations, suggesting that some additional factor(s) must influence the degree of reduction of 24-hour intragastric acidity. Thus, when determining the optimal dose of omeprazole for acid inhibition, the route and duration of administration must be taken into consideration; after 5 days of once-daily administration of doses as low as 10 mg IV and 20 mg orally are effective and dependable in reducing 24-hour intragastric acidity in patients with duodenal ulcer. However, a daily dose of 40 mg IV omeprazole is not sufficient to keep intragastric pH above 4 in all patients during the first day of treatment.
authors.affiliation: Clinical Pharmacology, Astra Hässle AB, Mölndal, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Cederberg
authors.forename: A B
authors.initials: AB
authors.lastname: Thomson
authors.forename: V
authors.initials: V
authors.lastname: Mahachai
authors.forename: J A
authors.initials: JA
authors.lastname: Westin
authors.forename: P
authors.initials: P
authors.lastname: Kirdeikis
authors.forename: D
authors.initials: D
authors.lastname: Fisher
authors.forename: L
authors.initials: L
authors.lastname: Zuk
authors.forename: B
authors.initials: B
authors.lastname: Marriage
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D002940:Circadian Rhythm; D004334:Drug Administration Schedule; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D006207:Half-Life; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics
chemical_list: D009853:Omeprazole